283 related articles for article (PubMed ID: 37833617)
61. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
62. Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Bokhari L; Sinclair R
Int J Dermatol; 2018 Dec; 57(12):1464-1470. PubMed ID: 30160787
[TBL] [Abstract][Full Text] [Related]
63. Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib.
Cai L; Wei Y; Zhao M; Zhuo J; Tao X; Lin M
Front Med (Lausanne); 2023; 10():1253795. PubMed ID: 37877023
[TBL] [Abstract][Full Text] [Related]
64. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
[TBL] [Abstract][Full Text] [Related]
65. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
[TBL] [Abstract][Full Text] [Related]
66. A description of alopecia areata in European patients based on real-world survey data: physician-reported characterization of severity and associated treatment utilization.
Galván SV; Piraccini BM; Reygagne P; Farrant P; Reed C; Johansson E; Marwaha S; Durand F; Blume-Peytavi U
Eur J Dermatol; 2023 Dec; 33(6):648-656. PubMed ID: 38465546
[TBL] [Abstract][Full Text] [Related]
67. Baricitinib: A Review in Moderate to Severe Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2022 May; 23(3):409-420. PubMed ID: 35503162
[TBL] [Abstract][Full Text] [Related]
68. Effectiveness and safety of baricitinib in patients with alopecia areata: a systematic review and Meta-analysis of randomized controlled trials.
Mahmoud AM
Curr Med Res Opin; 2023 Feb; 39(2):249-257. PubMed ID: 36239359
[TBL] [Abstract][Full Text] [Related]
69. Scalp hair regrowth is associated with improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata: results from two randomized controlled trials.
Piraccini BM; Ohyama M; Craiglow B; Bewley A; Ding Y; Chen YF; Dutronc Y; Pierce E; Durand F; Mostaghimi A
J Dermatolog Treat; 2023 Dec; 34(1):2227299. PubMed ID: 37381691
[TBL] [Abstract][Full Text] [Related]
70. An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis.
Jabbari A; Sansaricq F; Cerise J; Chen JC; Bitterman A; Ulerio G; Borbon J; Clynes R; Christiano AM; Mackay-Wiggan J
J Invest Dermatol; 2018 Jul; 138(7):1539-1545. PubMed ID: 29452121
[TBL] [Abstract][Full Text] [Related]
71. Protocol for a systematic review and meta-analysis on Janus kinase inhibitors in the management of vitiligo.
Pranić S; Pulumati A; Vuković D
Syst Rev; 2024 Apr; 13(1):110. PubMed ID: 38641831
[TBL] [Abstract][Full Text] [Related]
72. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
Stefanis AJ
Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
[TBL] [Abstract][Full Text] [Related]
73. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
74. The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review.
de Oliveira AB; Alpalhão M; Filipe P; Maia-Silva J
Dermatol Ther; 2019 Sep; 32(5):e13053. PubMed ID: 31381252
[TBL] [Abstract][Full Text] [Related]
75. The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials.
Wyrwich KW; Kitchen H; Knight S; Aldhouse NVJ; Macey J; Nunes FP; Dutronc Y; Mesinkovska N; Ko JM; King BA
Br J Dermatol; 2020 Oct; 183(4):702-709. PubMed ID: 31970750
[TBL] [Abstract][Full Text] [Related]
76. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K;
Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697
[TBL] [Abstract][Full Text] [Related]
77. A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience.
Taylor PC; Laedermann C; Alten R; Feist E; Choy E; Haladyj E; De La Torre I; Richette P; Finckh A; Tanaka Y
J Clin Med; 2023 Jul; 12(13):. PubMed ID: 37445562
[TBL] [Abstract][Full Text] [Related]
78. Tofacitinib as a pragmatic treatment choice for alopecia areata: A retrospective review.
Benton S; Farah R; Freese R; Hordinsky M
Dermatol Ther; 2022 Apr; 35(4):e15310. PubMed ID: 34997820
[TBL] [Abstract][Full Text] [Related]
79. Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors.
Paggioli I; Moss J
J Autoimmun; 2022 Dec; 133():102926. PubMed ID: 36335798
[TBL] [Abstract][Full Text] [Related]
80. Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.
Papierzewska M; Waśkiel-Burnat A; Rudnicka L
Clin Drug Investig; 2023 May; 43(5):325-334. PubMed ID: 37138134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
